Cargando…

Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma

PURPOSE: Ipilimumab (IPI), a monoclonal antibody against immune-checkpoint receptor cytotoxic T lymphocyte antigen-4, is designed to enhance antitumor T cell function. IPI 10 mg/kg plus dacarbazine (DTIC) significantly improved overall survival in a phase 3 study involving predominantly Caucasian pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yamazaki, N., Uhara, H., Fukushima, S., Uchi, H., Shibagaki, N., Kiyohara, Y., Tsutsumida, A., Namikawa, K., Okuyama, R., Otsuka, Y., Tokudome, T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612320/ https://www.ncbi.nlm.nih.gov/pubmed/26407818 http://dx.doi.org/10.1007/s00280-015-2870-0

Ejemplares similares

Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma
por: Yamazaki, N., et al.
Publicado: (2015)

Five‐year survival with nivolumab in previously untreated Japanese patients with advanced or recurrent malignant melanoma
por: Uhara, Hisashi, et al.
Publicado: (2021)

Final analysis of a phase II study of nivolumab in combination with ipilimumab for unresectable chemotherapy‐naive advanced melanoma
por: Namikawa, Kenjiro, et al.
Publicado: (2020)

Efficacy and safety of nivolumab in Japanese patients with previously untreated advanced melanoma: A phase II study
por: Yamazaki, Naoya, et al.
Publicado: (2017)

Long‐term follow up of nivolumab in previously untreated Japanese patients with advanced or recurrent malignant melanoma
por: Yamazaki, Naoya, et al.
Publicado: (2019)

Sequential Combination Chemotherapy of Dacarbazine (DTIC) with Carboplatin and Paclitaxel for Patients with Metastatic Mucosal Melanoma of Nasal Cavity and Paranasal Sinuses
por: Omata, W., et al.
Publicado: (2017)

Real‐world safety and efficacy data of ipilimumab in Japanese radically unresectable malignant melanoma patients: A postmarketing surveillance
por: Yamazaki, Naoya, et al.
Publicado: (2020)

Q-TWiST analysis comparing ipilimumab/dacarbazine vs placebo/dacarbazine for patients with stage III/IV melanoma
por: Sherrill, B, et al.
Publicado: (2013)

Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma
por: Long, Georgina V, et al.
Publicado: (2015)

Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma
por: Amin, Asim, et al.
Publicado: (2016)

Characteristics of adverse drug reactions in a vemurafenib early post-marketing phase vigilance study in Japan
por: Uhara, H., et al.
Publicado: (2017)

Randomized phase III trial of adjuvant therapy with locoregional interferon beta versus surgery alone in stage II/III cutaneous melanoma: Japan Clinical Oncology Group Study (JCOG1309, J-FERON)
por: Namikawa, Kenjiro, et al.
Publicado: (2017)

Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Japanese subgroup analysis from the phase 3 CheckMate 238 study
por: Yokota, Kenji, et al.
Publicado: (2019)

Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma
por: Chesney, Jason, et al.
Publicado: (2019)

Clinical outcomes of previously untreated patients with unresectable intrahepatic cholangiocarcinoma following proton beam therapy
por: Shimizu, Shosei, et al.
Publicado: (2019)

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Chapman, Paul B, et al.
Publicado: (2021)

A randomized phase 2 trial of nivolumab, gemcitabine, and cisplatin or nivolumab and ipilimumab in previously untreated advanced biliary cancer: BilT‐01
por: Sahai, Vaibhav, et al.
Publicado: (2022)

Phase 1/2 study assessing the safety and efficacy of dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation‐positive advanced cutaneous melanoma
por: Yamazaki, Naoya, et al.
Publicado: (2018)

A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma
por: Brohl, Andrew S., et al.
Publicado: (2016)

A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma
por: Middleton, M R, et al.
Publicado: (2000)

Pimasertib Versus Dacarbazine in Patients With Unresectable NRAS-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover
por: Lebbé, Celeste, et al.
Publicado: (2020)

Phase 1 results of a phase 1b/2, multicenter, open-label trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) vs ipi alone in previously untreated, unresected stage IIIB-IV melanoma
por: Puzanov, Igor, et al.
Publicado: (2013)

Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study)
por: Nakamura, Y., et al.
Publicado: (2021)

Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma
por: Yamazaki, Naoya, et al.
Publicado: (2017)

Treatment of metastatic malignant melanoma with dacarbazine, vindesine and cisplatin.
por: Pectasides, D., et al.
Publicado: (1989)

Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)
por: Boku, N, et al.
Publicado: (2019)

Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up
por: Tomita, Yoshihiko, et al.
Publicado: (2019)

Dacarbazine Combined Targeted Therapy versus Dacarbazine Alone in Patients with Malignant Melanoma: A Meta-Analysis
por: Jiang, Guan, et al.
Publicado: (2014)

Meta-Analysis of the Safety and Efficacy of Interferon Combined With Dacarbazine Versus Dacarbazine Alone in Cutaneous Malignant Melanoma
por: Xin, Yong, et al.
Publicado: (2016)

First-Line Genomic Profiling in Previously Untreated Advanced Solid Tumors for Identification of Targeted Therapy Opportunities
por: Matsubara, Junichi, et al.
Publicado: (2023)

Dacarbazine (DTIC)-based chemotherapy or chemoimmunotherapy of patients with disseminated malignant melanoma.
por: Mulder, N. H., et al.
Publicado: (1994)

Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma
por: Gibney, Geoffrey T., et al.
Publicado: (2019)

Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma
por: Daponte, Antonio, et al.
Publicado: (2013)

Tallimustine in advanced previously untreated colorectal cancer, a phase II study.
por: Punt, C. J., et al.
Publicado: (1996)

Successful Treatment of Unresectable Advanced Melanoma by Administration of Nivolumab With Ipilimumab Before Primary Tumor Resection
por: Fujimura, Taku, et al.
Publicado: (2019)

A population-based study of the treatment effect of first-line ipilimumab for metastatic or unresectable melanoma
por: Drysdale, Erik, et al.
Publicado: (2019)

First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis
por: Yang, Liu, et al.
Publicado: (2023)

Phase II study of irinotecan combined with carboplatin in previously untreated small-cell lung cancer
por: Kinoshita, A, et al.
Publicado: (2006)

Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment
por: Revicki, Dennis A, et al.
Publicado: (2012)

Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
por: Lamb, Yvette N.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_39lpv6lp5d9gkf8q2k7ks2tav6